Statistical Analysis & CDISC Transformation Service
InquiryOverview
In the high-stakes arena of anti-obesity therapeutic development, the ability to translate complex clinical data into a clear narrative of efficacy and safety is paramount. Protheragen offers specialized statistical analysis & CDISC transformation services, bridging the gap between raw clinical observations and rigorous regulatory evidence. By implementing the Global Clinical Data Interchange Standards Consortium (CDISC) standards, we ensure your data is structured, transparent, and ready for FDA/EMA scrutiny. Our biostatistical experts employ sophisticated modeling to uncover the true impact of metabolic interventions on weight loss, glycemic control, and cardiovascular outcomes.
Precision Analytics, Validating Efficacy - Advanced Biostatistics for Anti-Obesity Drug Development
Protheragen provides a comprehensive suite of analytical solutions tailored to the unique longitudinal nature of weight management trials. We specialize in converting disparate datasets into standardized, submission-ready packages while performing high-level biostatistical modeling to validate therapeutic hypotheses.
Expert CDISC Implementation & Data Mapping
We specialize in the end-to-end conversion of raw clinical data into study data tabulation model (SDTM) and analysis data model (ADaM) structures. This standardization facilitates seamless integration with the Database Construction & Data Management Service outputs, ensuring that datasets from clinical pharmacology studies of anti-obesity therapeutics are fully traceable and audit-ready. To support this architecture, we offer:
Integrated Summary of Efficacy (ISE) & Safety (ISS) Service
We perform cross-study data pooling and meta-analysis to provide a holistic view of the drug's profile across different trial phases and populations.
Advanced Statistical Modeling & Simulation
Our team utilizes mixed model repeated measures (MMRM) and intention-to-treat (ITT) principles to manage missing data and longitudinal weight variations, providing a robust statistical foundation for efficacy claims.
Regulatory Submission & Dossier Support
We prepare the electronic submission packages, including Define.xml files and reviewers' guides, ensuring total alignment with current regulatory requirements.
Advanced Safety Signaling
We apply rigorous statistical filters to identify and analyze adverse event trends related to various anti-obesity therapeutics. By integrating comprehensive clinical safety data, we evaluate the overall risk-benefit profile of novel small molecules and biologics. This involves determining the incidence and severity of adverse events while assessing their correlation with therapeutic efficacy. By quantifying potential risks and weighing them against observed benefits, we gain a nuanced understanding of safety profiles that inform clinical decision-making and regulatory evaluations, ultimately supporting the development of safer and more effective obesity treatments.
Subgroup & Exploratory Analysis
Beyond primary endpoints, we conduct in-depth post-hoc analyses to identify responders using clinical biomarker data. This approach allows researchers to examine individual patient responses within the broader study population, enhancing the ability to tailor effective treatment strategies. This precision medicine methodology is crucial in optimizing outcomes in obesity care, enabling customized interventions based on individual variability while minimizing risks associated with anti-obesity treatments.
Workflow
Protheragen employs a standardized, iterative workflow designed to transform raw clinical data into a high-fidelity evidence base. Our methodology emphasizes mathematical transparency and regulatory alignment, ensuring that every p-value and confidence interval is derived through validated, reproducible programming. By bridging the gap between clinical operations and final study reports, we provide a rigorous analytical framework that withstands the complexities of missing data and longitudinal variations inherent in weight-loss research.
Fill Out This Brief Inquiry Form to Receive an Actionable Strategic Consultation.
Applications
- Regulatory Efficacy Validation
Structuring phase II/III trial data into standardized formats to prove statistically significant weight reduction compared to placebo, ensuring the data is ready for FDA/EMA filing.
- Cardiometabolic Risk Assessment
Performing exploratory analyses to evaluate how anti-obesity agents influence secondary markers such as blood pressure, lipid profiles, and glycemic control across diverse patient cohorts.
- Long-term Maintenance Modeling
Applying time-to-event and survival analysis to evaluate the durability of weight-loss effects and the risk of weight regain over multi-year follow-up periods.
- Cardiovascular Outcome Trials (CVOT)
Integrating weight-loss data with cardiovascular event monitoring to assess the drug's impact on major adverse cardiovascular events (MACE) in high-risk populations.
Advantages
Submission-Ready Expertise
Our programmers are veterans of successful NDAs/BLAs, ensuring your data follows the latest CDISC implementation guides for immediate regulatory acceptance.
Sophisticated Modeling
From Bayesian approaches to complex mixed models, we provide the high-level math needed to handle the noise of real-world metabolic data.
Dual-Programming Validation
Every analysis is verified by a secondary independent programmer to ensure 100% accuracy and eliminate computational bias.
Integrated Analysis Capabilities
We excel at pooling data from multiple studies (ISE/ISS) to create a powerful, unified evidence base for market access and reimbursement strategies.
Comprehensive Clinical Research Solutions
Protheragen offers an integrated clinical service ecosystem spanning the full therapeutic development continuum, from early-phase clinical pharmacology to late-phase validation and post-market surveillance. Our analytical framework is meticulously designed to integrate with broader clinical research platforms, ensuring that data derived from diverse trial phases is harmonized, validated, and maximized for regulatory insight. By bridging the gap between clinical operations and biostatistical analysis, we provide a unified data environment that accelerates regulatory submission and market access.
Publication Data
Title: Statistical Analysis in Clinical Trials Using the Study Data Tabulation Model (SDTM) and the Analysis Dataset Model (ADaM): Effects, Obstacles, and Solutions
Journal: Int J Clin Biostat Biom, 2023.
DOI: https://doi.org/10.23937/2469-5831/1510052
Summary: In this study, researchers systematically reviewed the application of the SDTM and the ADaM in clinical trial statistical analysis. They evaluated standardized data domains, the CDISC implementation pathway, and the impact on data quality, operational efficiency, and regulatory submission readiness. The findings demonstrate that SDTM and ADaM standardization significantly enhances data consistency, traceability, and cross-study integration while reducing programming workload and accelerating FDA/EMA regulatory review. Key structures include SDTM domains for demographics, adverse events, and laboratory data, alongside ADaM datasets for efficacy endpoints, time-to-event analysis, and biomarker derivation. This work provides informative support for CDISC transformation and statistical analysis services in anti-obesity drug development.
Customer Review
Rapid Submission Turnaround
"Protheragen's ability to handle our SDTM mapping and ADaM programming allowed us to meet a very tight FDA submission window. Their attention to the Define.xml details was exceptional."
— R. K., Director of Biometrics
Precision in Complex Modeling
"The biostatistics team at Protheragen provided the sophisticated mixed-model analysis we needed to account for patient dropouts in our 2-year weight-loss study. Their results were robust and easily defended."
— Dr. M. L., VP of Clinical Development
Frequently Asked Questions
-
Why is CDISC transformation necessary for my study?
Regulatory agencies like the FDA and EMA require clinical data to be submitted in SDTM and ADaM formats. Transformation ensures that data is standardized, allowing reviewers to verify your results quickly.
-
How does dual-programming validation ensure the accuracy of statistical outputs?
Every analysis at Protheragen undergoes independent dual-programming validation. A secondary biostatistician replicates the analysis using distinct programming code to verify that all p-values, confidence intervals, and dataset derivations are reproducible. This cross-validation eliminates computational bias and ensures that SDTM/ADaM structures and statistical summaries withstand rigorous FDA/EMA regulatory review, providing an auditable trail of mathematical transparency for your submission package.
-
Can you help with missing data in weight-loss trials?
Yes. We employ advanced techniques such as multiple imputation and mixed model repeated measures (MMRM) to handle missing data points, ensuring that the intention-to-treat analysis remains valid and the results are not biased by patient withdrawals.
Protheragen is dedicated to providing the analytical rigor required to turn metabolic data into therapeutic breakthroughs. Whether you are conducting a global Phase III trial or any other clinical study, our biostatisticians ensure your evidence is beyond reproach. Contact us today to discuss your statistical and data transformation needs.
Reference
- Patel, S.K.; et al. Statistical Analysis in Clinical Trials Using the Study Data Tabulation Model (SDTM) and the Analysis Dataset Model (ADaM): Effects, Obstacles, and Solutions. Int J Clin Biostat Biom. 2023, 9, 052. (CC BY).
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.